Pablo Umaña Selected Research

Pablo Umaña Research Topics

Disease

32	Neoplasms (Cancer) 03/2024 - 02/2006
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2018
2	Persistent Infection 01/2023 - 10/2022
2	Squamous Cell Carcinoma of Head and Neck 01/2023 - 01/2021
2	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2023
2	Hematologic Neoplasms (Hematological Malignancy) 12/2019 - 10/2018
1	Lymphoma (Lymphomas) 03/2024
1	Melanoma (Melanoma, Malignant) 01/2024
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024
1	Cytokine Release Syndrome 11/2023
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2023
1	Adenocarcinoma 01/2023
1	Glioblastoma (Glioblastoma Multiforme) 10/2022
1	Virus Diseases (Viral Diseases) 10/2022
1	Carcinoma (Carcinomatosis) 01/2022
1	Fever (Fevers) 01/2022
1	Bites and Stings (Sting) 01/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Hypotension (Low Blood Pressure) 01/2022
1	Wilms Tumor (Wilm's Tumor) 12/2021
1	Leukemia 12/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Multiple Myeloma 01/2017

Drug/Important Bio-Agent (IBA)

9	Bispecific AntibodiesIBA 01/2024 - 12/2019
6	AntigensIBA 01/2023 - 01/2020
5	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2016
5	CytokinesIBA 11/2023 - 01/2021
5	AntibodiesIBA 01/2020 - 03/2013
4	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 12/2019
4	cibisatamabIBA 01/2022 - 01/2016
3	glofitamabIBA 03/2024 - 01/2021
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2022 - 01/2021
3	Carcinoembryonic AntigenIBA 01/2022 - 01/2016
2	venetoclaxIBA 01/2024 - 01/2018
2	ErbB Receptors (EGF Receptor)IBA 10/2022 - 03/2013
2	Peptides (Polypeptides)IBA 01/2022 - 12/2021
2	serum P-component (CIt)IBA 01/2022 - 01/2021
2	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2020
2	obinutuzumabIBA 10/2018 - 01/2018
2	Immunoglobulin G (IgG)IBA 01/2016 - 03/2013
1	Azacitidine (5 Azacytidine)FDA Link 01/2024
1	Monophenol Monooxygenase (Tyrosinase)IBA 01/2024
1	RNA (Ribonucleic Acid)IBA 11/2022
1	Immunoglobulins (Immunoglobulin)IBA 11/2022
1	MucinsIBA 11/2022
1	SuspensionsIBA 11/2022
1	Programmed Cell Death 1 ReceptorIBA 11/2022
1	epidermal growth factor receptor VIIIIBA 10/2022
1	InterleukinsIBA 10/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	InterferonsIBA 01/2022
1	TL8-506IBA 01/2022
1	Toll-Like Receptor AgonistsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	ChemokinesIBA 01/2022
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 01/2022
1	Toll-Like Receptor 8IBA 01/2022
1	Caspase 3 (Caspase-3)IBA 01/2022
1	Glycoproteins (Glycoprotein)IBA 01/2022
1	RMFPNAPYLIBA 12/2021
1	WT1 ProteinsIBA 12/2021
1	HLA-A Antigens (HLA-A)IBA 12/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Dasatinib (BMS 354825)FDA Link 01/2021
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2020
1	Immunoglobulin Fab FragmentsIBA 01/2020
1	LuciferasesIBA 12/2019
1	Granzymes (Granzyme)IBA 12/2019
1	RG7388IBA 01/2018
1	Interleukin-2 (IL2)IBA 01/2017
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2017
1	aldesleukin (Proleukin)FDA Link 01/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016
1	Antineoplastic Agents (Antineoplastics)IBA 01/2016
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2016
1	imgatuzumabIBA 01/2016
1	Cetuximab (Erbitux)FDA Link 03/2013
1	Fc Receptors (Fc Receptor)IBA 03/2013
1	Tyrosine Kinase InhibitorsIBA 03/2013
1	Monoclonal AntibodiesIBA 01/2013

Therapy/Procedure

10	Immunotherapy 10/2023 - 01/2017
8	Therapeutics 10/2023 - 02/2006
3	Radiotherapy 01/2023 - 01/2021
2	Drug Therapy (Chemotherapy) 01/2018 - 01/2016
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021
1	Premedication 01/2016